coli

NIEHS Researchers Identify Enzyme Critical in DNA Replication

...fferentpolymerase. In lower organisms like the E. coli bacteria that Kornbergstudied, one DNA polymerase can accomplish both tasks. However,humans and related higher organisms, such as bakers yeast, are muchmore complicated. Recent discoveries, several of which emerged fromthe human genome project, indic...

Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO

...roduct for the treatment ofShigatoxin-producing E. coli bacterial infections; ECO-4601, anovel anticancer therapy derived from a nonpathogenicmicroorganism; and CAP-232, a targeted therapy with potentialefficacy in multiple oncology indications. Thallion has twoproprietary technology platforms: CellCarta&...

Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

...tion ofCholeraGarde® (Peru-15), Ty800, ETEC E. coli vaccine, VLPs andother products and AVANT’s expectations regarding marketgrowth; (4) the cost, timing, scope and results of ongoing safetyand efficacy trials of CholeraGarde® (Peru-15), Ty800, ETEC E.coli vaccine and other preclinical and c...

Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

...trials of CholeraGarde(R) (Peru-15),Ty800, ETEC E. coli vaccine and other preclinical and clinicaltesting; (5) the ability to negotiate strategic partnerships orother disposition transactions for AVANT's cardiovascular programs,including TP10 and CETi; (6) the ability of AVANT to managemultiple clinical t...

Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers' Diarrhea Stimulates Immune Response Even at Low Doses

...erate an immuneresponse against enterotoxigenic E. coli (ETEC) bacteria -- themost common cause of travelers' diarrhea. Researchers found thateven at the lowest dose tested, an Iomai patch applied to the armgenerated a robust response in more than 95 percent ofpatients. The results were presented today b...

Adnexus Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) on Clinical Product Candidate, CT-322

...e half life, favorable IP profileand high yield E. coli production. Adnectins are designed using the PROfusion System, Adnexus'patented protein design engine, to achieve high potency andspecificity for a therapeutic target while simultaneously selectingfor ideal pharmaceutical product characteristics. PR...

Vaxiion Researchers Discover Novel Vaccine Delivery System in Collaboration with San Diego State University

...mponent vaccine against Salmonella, Shigellaand E. coli for use in human clinical trials," Sabbadini said. Other co-authors of the study include Yen-Lin Chu of SDSU; NeilL. Berkley, co-founder of Vaxiion Therapeutics Inc. who receivedboth M.S. and MBA degrees at SDSU; and Maria Salvato and Juan C.Zapata ...